Hunan Er Kang Pharmaceutical Market Cap ($890.38 Million)
Market Cap & Net Worth: Hunan Er Kang Pharmaceutical (300267)
Hunan Er Kang Pharmaceutical market cap. Hunan Er Kang Pharmaceutical (SHE:300267) has a market capitalization of $890.38 Million (CN¥6.08 Billion) as of November 5, 2026. Listed on the SHE stock exchange, this China-based company holds position #9116 globally and #2200 in its home market, demonstrating a 6.50% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hunan Er Kang Pharmaceutical's stock price CN¥2.95 by its total outstanding shares 2062604870 (2.06 Billion). Also see cash flow conversion of Hunan Er Kang Pharmaceutical for how efficiently the company converts equity into cash flow.
Hunan Er Kang Pharmaceutical Market Cap History (2015–2026)
Hunan Er Kang Pharmaceutical market cap history from 2015 to 2026. Data shows change from $4.89 Billion to $890.38 Million (-13.92% CAGR). Check today's stock price for Hunan Er Kang Pharmaceutical for real-time trading data and today's change.
Hunan Er Kang Pharmaceutical Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hunan Er Kang Pharmaceutical's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 300267 year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.74x
Hunan Er Kang Pharmaceutical's market cap is 0.74 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $4.89 Billion | $1.54 Billion | $604.58 Million | 3.17x | 8.09x |
| 2016 | $3.81 Billion | $2.96 Billion | $1.03 Billion | 1.29x | 3.71x |
| 2017 | $1.97 Billion | $2.83 Billion | $522.46 Million | 0.70x | 3.77x |
| 2018 | $1.13 Billion | $2.35 Billion | $216.58 Million | 0.48x | 5.24x |
| 2019 | $1.52 Billion | $2.74 Billion | $161.53 Million | 0.55x | 9.41x |
| 2020 | $1.24 Billion | $2.38 Billion | $202.22 Million | 0.52x | 6.15x |
| 2021 | $1.42 Billion | $2.24 Billion | -$791.20 Million | 0.63x | N/A |
| 2022 | $1.06 Billion | $1.87 Billion | $45.76 Million | 0.57x | 23.20x |
| 2023 | $968.85 Million | $1.78 Billion | -$195.32 Million | 0.54x | N/A |
| 2024 | $839.07 Million | $1.14 Billion | -$373.37 Million | 0.74x | N/A |
Competitor Companies of 300267 by Market Capitalization
Companies near Hunan Er Kang Pharmaceutical in the global market cap rankings as of November 5, 2026. Also see Hunan Er Kang Pharmaceutical (300267) total assets for a full breakdown of the balance sheet.
Key companies related to Hunan Er Kang Pharmaceutical by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Hunan Er Kang Pharmaceutical (2015–2026)
Market capitalization of Hunan Er Kang Pharmaceutical from 2015 to today. Between 2015 and today, Hunan Er Kang Pharmaceutical's market cap moved from $4.89 Billion to $ 890.38 Million, with a yearly change of -13.92%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥890.38 Million | -13.49% |
| 2025 | CN¥1.03 Billion | +22.66% |
| 2024 | CN¥839.07 Million | -13.40% |
| 2023 | CN¥968.85 Million | -8.73% |
| 2022 | CN¥1.06 Billion | -25.11% |
| 2021 | CN¥1.42 Billion | +14.05% |
| 2020 | CN¥1.24 Billion | -18.22% |
| 2019 | CN¥1.52 Billion | +33.93% |
| 2018 | CN¥1.13 Billion | -42.37% |
| 2017 | CN¥1.97 Billion | -48.34% |
| 2016 | CN¥3.81 Billion | -22.05% |
| 2015 | CN¥4.89 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Hunan Er Kang Pharmaceutical was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $890.38 Million USD |
| MoneyControl | $890.38 Million USD |
| MarketWatch | $890.38 Million USD |
| marketcap.company | $890.38 Million USD |
| Reuters | $890.38 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hunan Er Kang Pharmaceutical
Hunan Er-Kang Pharmaceutical Co., Ltd manufactures and sells APIs, finished drug products, and pharmaceutical excipients in China and internationally. Its APIs include glycerin, dilute hydrochloric acid, sulbenicillin sodium, dihydroxypropyl theophylline, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. The company's finished drugs primarily comprise sulbenicillin sodium for i… Read more